Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg.
One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41. 3% vs 13. 0%; P
International journal of impotence research. 2015 Oct 29 [Epub ahead of print]
T-H Kim, Y-S Ha, S H Choi, E S Yoo, B W Kim, S-J Yun, W-J Kim, Y S Kwon, T G Kwon
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea. , Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea. , Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea. , Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea. , Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea. , Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea. , Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea. , Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. , Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.